Hubbs Lab
  • Research
  • Pipeline
  • Screening
  • Tools ▾
    • Drug Repurposing
    • Drug Design
    • ASO Discovery
  • Publications
  • People
  • Contact
Open Positions

Publications & Patents

  • 2025
    Non-muscle myosin II inhibition at the site of axon injury increases axon regeneration
    Heo K, Ho TS, Zeng X, Turnes BL, ..., Hubbs JL, ..., Bhatt D
    Nature Communications
    PubMed DOI
  • 2024
    Substituted phenols as ion channel binders Patent Pending
    Bean BP, Woolf CJ, Hubbs JL
    WO 2024/259383 · Boston Children's Hospital
  • 2024
    Tetrahydroimidazopyridine-benzothiazole compounds as ATG9A modulators for neurological diseases Patent Pending
    Ebrahimi-Fakhari D, Sahin M, Hubbs JL, Satoh M
    WO 2024/243015 · Boston Children's Hospital
  • 2024
    High-content screening identifies a small molecule that restores AP-4-dependent protein trafficking in neuronal models of AP-4-associated hereditary spastic paraplegia
    Saffari A, Brechmann B, Boger C, Afshar-Saber W, ..., Hubbs JL, ..., Bhatt DK
    Nature Communications
    PubMed DOI
  • 2024
    ALDH5A1-deficient iPSC-derived excitatory and inhibitory neurons display cell type specific alterations
    Afshar-Saber W, Teaney NA, Winden KD, Jumo H, ..., Hubbs JL, ..., Bhatt DK
    Neurobiology of Disease
    PubMed DOI
  • 2024
    GABAA positive allosteric modulator crystalline salts (p-toluenesulfonic acid) Patent
    Toczko M, Hubbs JL, Ning Y, Li ZJ, He Y, Liu X
    US 12,134,619 · Neurocycle Therapeutics
  • 2023
    GABAA positive allosteric modulator compounds for treatment of itch and/or dermatitis Patent
    Toczko M, Hubbs JL
    US 11,571,421 · Neurocycle Therapeutics
  • 2023
    GABAA positive allosteric modulator crystalline salts (phosphoric acid) Patent
    Toczko M, Hubbs JL
    US 11,542,263 · Neurocycle Therapeutics
  • 2023
    Treatment of epileptic conditions with GABAA receptor modulators Patent Pending
    Hubbs JL, Toczko M
    US 2023/0020036 · Neurocycle Therapeutics
  • 2022
    Use of GABAA receptor modulators for the treatment of pain Patent Pending
    Toczko M, Hubbs JL
    US 2022/0152037 · Neurocycle Therapeutics
  • 2021
    Histone deacetylase inhibitors Patent
    Grimm JB, Hubbs JL, Miller T, Otte KM, Siliphaivanh P, Stanton MG, Wilson K, Witter D, Zhou H
    US 10,981,933 · BioMarin Pharmaceutical
  • 2020
    Histone deacetylase inhibitors Patent
    Grimm JB, Hubbs JL, Miller T, Otte KM, Siliphaivanh P, Stanton MG, Wilson K, Witter D, Zhou H
    US 10,526,346 · BioMarin Pharmaceutical
  • 2019
    GABAA positive allosteric modulator compounds, methods of making, and uses thereof Patent Pending
    Toczko M, Hubbs JL
    WO 2019/204446 · Neurocycle Therapeutics
  • 2019
    N-substituted 4-aminoquinazoline derivatives and methods of use Patent
    Huisman GW, Hubbs JL, Zhang X, Osborne R
    US 10,273,229 · Codexis
  • 2019
    HDAC inhibitors Patent
    Grimm JB, Hubbs JL, Miller T, Otte KM, Siliphaivanh P, Stanton MG, Wilson K, Witter D, Zhou H
    US 10,428,028 · BioMarin Pharmaceutical
  • 2019
    Histone deacetylase inhibitors Patent
    Grimm JB, Hubbs JL, Miller T, Otte KM, Siliphaivanh P, Stanton MG, Wilson K, Witter D, Zhou H
    US 10,301,323 · BioMarin Pharmaceutical
  • 2019
    Histone deacetylase inhibitors Patent
    Grimm JB, Hubbs JL, Miller T, Otte KM, Siliphaivanh P, Stanton MG, Wilson K, Witter D, Zhou H
    US 10,280,182 · BioMarin Pharmaceutical
  • 2018
    Itch suppression in mice and dogs by modulation of spinal α2 and α3 GABAA receptors
    Ralvenius WT, Neumann E, Pagani M, Acuna MA, ..., Hubbs JL, ..., Zeilhofer HU
    Nature Communications
    PubMed DOI
  • 2018
    Imidazoyl anilide derivatives and methods of use Patent
    Huisman GW, Hubbs JL, Zhang X, Osborne R
    US 10,045,987 · Codexis
  • 2018
    Histone deacetylase inhibitors Patent
    Grimm JB, Hubbs JL, Miller T, Otte KM, Siliphaivanh P, Stanton MG, Wilson K, Witter D, Zhou H
    US 10,059,723 · BioMarin Pharmaceutical
  • 2018
    HDAC inhibitors Patent
    Grimm JB, Hubbs JL, Miller T, Otte KM, Siliphaivanh P, Stanton MG, Wilson K, Witter D, Zhou H
    US 10,029,988 · BioMarin Pharmaceutical
  • 2015
    Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators
    Hubbs JL, Fuller NO, Austin WF, Shen R, ..., Bronk BS
    Bioorganic & Medicinal Chemistry Letters
    PubMed DOI
  • 2013
    Efficacy of SPI-1865, a novel gamma-secretase modulator, in multiple rodent models
    Loureiro RM, Dumin JA, McKee TD, Austin WF, Fuller NO, Hubbs JL, ..., Tate B
    Alzheimer's Research & Therapy
    PubMed DOI
  • 2012
    Modulation of gamma-secretase for the treatment of Alzheimer's disease
    Tate B, McKee TD, Loureiro RM, Dumin JA, ..., Hubbs JL, ..., Bronk BS
    International Journal of Alzheimer's Disease
    PubMed DOI
  • 2012
    Optimization of a natural product-based class of gamma-secretase modulators
    Hubbs JL, Fuller NO, Austin WF, Shen R, ..., Bronk BS
    Journal of Medicinal Chemistry
    PubMed DOI
  • 2012
    Initial optimization of a new series of gamma-secretase modulators derived from a triterpene glycoside
    Fuller NO, Hubbs JL, Austin WF, Creaser SP, ..., Bronk BS
    ACS Medicinal Chemistry Letters
    PubMed DOI
  • 2010
    Purine derivatives as potent gamma-secretase modulators
    Rivkin A, Ahearn SP, Chichetti SM, Hamblett CL, ..., Hubbs JL, ..., Shearman MS
    Bioorganic & Medicinal Chemistry Letters
    PubMed DOI
  • 2010
    Benzothiophene derivatives Patent
    Hubbs JL, Mampreian DM, Methot JL, Miller TA, Otte KM, Siliphaivanh P, Sloman DL, Stanton MG, Wilson KJ, Witter DJ
    US 7,834,034 · Merck Sharp & Dohme
  • 2010
    Benzothiophene hydroxamic acid derivatives Patent
    Hubbs JL, Kattar S, Methot J, Miller T, Siliphaivanh P, Stanton M, Wilson K, Witter DJ
    US 7,772,238 · Merck Sharp & Dohme
  • 2008
    Amino acid derivatives as histone deacetylase inhibitors
    Hubbs JL, Zhou H, Kral AM, Fleming JC, ..., Miller TA
    Bioorganic & Medicinal Chemistry Letters
    PubMed DOI
  • 2003
    Multigram synthesis of the C29-C51 subunit and completion of the total synthesis of altohyrtin C (spongistatin 2)
    Heathcock CH, McLaughlin M, Medina J, Hubbs JL, ..., Ott GR
    Journal of the American Chemical Society
    PubMed DOI
  • 2003
    A second-generation synthesis of the C1-C28 portion of the altohyrtins (spongistatins)
    Hubbs JL, Heathcock CH
    Journal of the American Chemical Society
    PubMed DOI
  • 2003
    Ni(II) bis(oxazoline)-catalyzed enantioselective syn aldol reactions of N-propionylthiazolidinethiones in the presence of silyl triflates
    Evans DA, Downey CW, Hubbs JL
    Journal of the American Chemical Society
    PubMed DOI
  • 1999
    Total synthesis of (±)-isoschizogamine
    Hubbs JL, Heathcock CH
    Organic Letters
    PubMed DOI
Rosamund Stone Zander and Hansjorg Wyss Translational Neuroscience Center Boston Children's Hospital Harvard Medical School
Translational Neuroscience Center · Boston Children's Hospital · Harvard Medical School
CLS 13070, 3 Blackfan Circle, Boston MA 02115